ASH-EHA Translational Research Training in Hematology

The Translational Research Training in Hematology (TRTH) is a prestigious, year-long mentoring and career development program jointly organized by the American Society of Hematology (ASH) and the European Hematology Association (EHA). It supports early-career researchers—including senior postdoctoral fellows and junior faculty—by equipping them with critical tools, mentoring, and networking opportunities to launch successful careers in blood-related translational research.

Led by international leaders in hematology, the program covers essential topics including biostatistics, biomarkers, molecular biology, genetics, ethics, and early-phase clinical trial design. TRTH is highly competitive, selecting 24 participants annually (12 from North America, 12 from Europe).

Eligibility Criteria:

Senior postdoctoral fellows or junior faculty
Engaged in blood-related translational research
Must be based in North America or Europe
Letter of Intent (LOI) is required before full application

Funding Details:

TRTH is a fully supported program, covering participation in the Spring Course, EHA Congress, and ASH Annual Meeting
Travel and accommodation costs are included for selected fellows
No direct monetary grant is provided, but the program offers in-kind support and high-value mentorship

Key Dates:

LOI Available: March 15, 2025
LOI Deadline: June 26, 2025, at 11:59 PM ET
Full Application Deadline (by invitation only): September 19, 2025
Award Notification: December 2025
Spring Course: March 13–20, 2026 (Leesburg, Virginia, USA)
EHA Congress: June 11–14, 2026
ASH Annual Meeting & Exposition: December 2026

Further Information:

Email: [email protected]

Website: www.hematology.org

For support inquiries: [email protected]

ASH biomarkers biostatistics blood-related research cancer career development clinical trial design Early-career researchers EHA hematology research junior faculty mentoring program OncoDaily Oncology postdoctoral fellows Translational Research Training in Hematology TRTH

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action